多西他赛药物基因组学研究进展  

Advances in pharmaconenomic studies of duoxetacel

作　　者：吴萍[1] 邹素兰[1] 倪雪峰[2] 

机构地区：[1]苏州大学医学院附属第三医院药剂科,江苏常州213003 [2]苏州大学医学院附属第三医院肿瘤科,江苏常州213003

出　　处：《中国临床药理学杂志》2015年第24期2486-2488,2491,共4页The Chinese Journal of Clinical Pharmacology

基　　金：江苏省药学会奥赛康临床药学研究课题基金资助项目(KY201379);常州市青年医学创新人才项目基金资助项目(KY201132)

摘　　要：多西他赛广泛用于乳腺癌、非小细胞肺癌、前列腺癌等多种肿瘤的治疗,然而,多西他赛临床疗效和不良反应的个体差异近年来受到越来越多的关注,国内外相关文献提示药物代谢相关基因的遗传变异是导致个体差异的重要原因之一。本文就细胞色素P450酶、多药耐药基因、药物转运体的基因多态性与多西他赛在体内的药代动力学/药效学个体差异及其与临床疗效与不良反应的相关性做一综述。Docetaxel is widely used in the treatment of breast cancer,non- small cell lung cancer,prostate cancer and other cancer.However,individual differences in clinical efficacy and adverse drug reactions of docetaxel have attracted more and more attention in recent years.Domestic and foreign literatures have suggested that the genetic variation of drug metabolism related genes is one of the important reasons leading to individual differences.In this paper,correlations between genetic polymorphism of cytochrome P450 enzymes,multidrug resistance gene,drug transporters of docetaxel and individual difference of pharmacokinetics/pharmacodynamics,clinical efficacy and adverse drug reactions of duoxetacel are reviewed.

关 键 词：多西他赛 药物基因组 基因多态性 抗肿瘤药物 个体化治疗 

分 类 号：R979.1[医药卫生—药品] R968[医药卫生—药学]